Clinical Trial Update: L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluates L-TIL plus tislelizumab for PD-1 antibody–resistant advanced non-small cell lung cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L-TIL
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Quanli Gao | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING